Core Insights - Alumis (ALMS) stock surged after positive Phase 3 results for envudeucitinib, a treatment for psoriasis, indicating strong symptom improvement compared to existing therapies [1][3] - The drug met all primary and secondary endpoints, positioning Alumis as a serious competitor in the multibillion-dollar psoriasis market [3][4] - Rapid efficacy onset, with improvements noted as early as week four, suggests potential to redefine treatment standards [4] Market Potential - The psoriasis market is valued at tens of billions of dollars annually, and even modest market penetration could lead to significant upside for Alumis [5] - The company’s pipeline includes additional immunology assets, providing diversification beyond psoriasis [5] Future Outlook - Positive sentiment in the biotech sector is expected to improve by 2026, with bullish options contracts indicating a potential 15% rally for ALMS, possibly reaching around $19 in the next four months [6]
Should You Chase the Rally in Alumis Stock Today?